Endo begins Mersana's foray into antibody-drug conjugates with $270 million deal

Mersana Therapeutics announced a collaboration agreement with Endo Pharmaceuticals worth up to $270 million plus royalties, its first deal in antibody-drug conjugates (ADCs).